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Pharmaceutical Sciences, Central South University, Changsha, China, 3Department of Cancer Biology and Toxicology,
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DNA repair pathways are triggered to maintain genetic stability and integrity when
mammalian cells are exposed to endogenous or exogenous DNA-damaging agents.
The deregulation of DNA repair pathways is associated with the initiation and progression
of cancer. As the primary anti-cancer therapies, ionizing radiation and chemotherapeutic
agents induce cell death by directly or indirectly causing DNA damage, dysregulation of the
DNA damage response may contribute to hypersensitivity or resistance of cancer cells to
genotoxic agents and targeting DNA repair pathway can increase the tumor sensitivity to
cancer therapies. Therefore, targeting DNA repair pathways may be a potential therapeutic
approach for cancer treatment. A better understanding of the biology and the regulatory
mechanisms of DNA repair pathways has the potential to facilitate the development of
inhibitors of nuclear and mitochondria DNA repair pathways for enhancing anticancer
effect of DNA damage-based therapy.
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THE DNA REPAIR PATHWAYS
A variety of endogenous and exogenous DNA-damaging agents such as UV light, ionizing radiation
(IR) and chemotherapeutic agents can lead to DNA lesions, including mismatches, single-strand
breaks (SSBs), double-strand breaks (DSBs), chemical modifications of the bases or sugars, and
interstrand or intrastrand cross-links. If the damage is not corrected, it will cause genomic instability
and mutation, which is one of the cancer hallmarks (Hanahan and Weinberg, 2011). In order to
prevent this situation, cells have evolved a series of mechanisms called DNA damage response (DDR)
in order to deal with such lesions. DDR is a complex network that functions in different ways to
target various DNA lesions, including signal transduction, transcriptional regulation, cell-cycle
checkpoints, induction of apoptosis, damage tolerance processes, and multiple DNA repair pathways
(Figure 1) (Giglia-Mari et al., 2011; Tian et al., 2015).
In mammalian cells, the two main organelles containing DNA are nucleus and mitochondria.
Nuclear DNA (nDNA) repair systems are divided into the following major pathways: 1) direct
reversal, which mainly repairs the lesion induced by alkylating agents, 2) base excision repair (BER),
aiming at DNA breaks (SSBs) and non-bulky impaired DNA bases, 3) nucleotide excision repair
(NER), correcting bulky, helix-distorting DNA lesions, 4) mismatch repair (MMR), repair of
insertion/deletion loops (IDLs) and base-base mismatch, 5) recombinational repair, which is
further divided into homologous recombination repair (HRR) and non-homologous end joining
(NHEJ), primarily functioning at DNA double strand breaks, 6) alternative nonhomologous end
joining (alt-NHEJ, MMEJ), involved in repair of DSBs, 7) translesion synthesis (TLS), which is more
likely to be a DNA damage tolerance mechanism (Jackson and Bartek, 2009; Hosoya and Miyagawa,
2014). Mitochondrial DNA (mtDNA) repair pathways, including the direct reversal, BER, MMR,
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TLS and double-strand break repair (DSBR), can repair damaged
DNA to maintain mitochondria genetic integrity, protect
mtDNA against oxidative damage, and promote cell survival
(Ohta, 2006; Saki and Prakash, 2017).
ROLE OF DNA REPAIR PATHWAYS IN
CANCER BIOLOGY
DNA repair pathways play an important role in the maintenance
of genome stability and integrity through correcting the impaired
DNA that may contribute to carcinogenesis (Clementi et al.,
2020). Numerous studies have indicated that certain cancers are
associated with the defect or mutation in the proteins of nuclear
or mitochondrial DNA repair pathways (Pearl et al., 2015;
Cerrato et al., 2016). For example, the defect in the
ATM–Chk2–p53 pathway, which plays a crucial role in DNA
double-strand breaks repair, promoted glioblastoma multiforme
(GBM) formation and contributed to GBMs radiation resistance
(Squatrito et al., 2010). The human syndrome hereditary
nonpolyposis colorectal cancer (HNPCC), which connects with
high degrees of microsatellite instability, is caused by germline
mutations in MMR genes, and the tumorigenesis of this disease is
connected with the defect in the MMR pathway (Hampel et al.,
2005). People who carry an MMR gene mutation have the
increased risk of a wide variety of cancers than their
noncarrier relatives (Win et al., 2012). Two important
homologous recombination (HR) DNA repair-related genes,
BRCA1 and BRCA2 germline mutant confer the genetic
predisposition to breast, ovarian cancer and pancreatic cancer
(Riaz et al., 2017). In addition, the tumor microenvironment
characteristic of hypoxia, low pH and nutrient deficiency, can
give rise to genomic instability and tumor progress through
downregulating DNA repair pathway. It has been reported
that hypoxic circumstance can result in the reduction of
MLH1 expression, a core protein in the MMR pathway
(Mihaylova et al., 2003). The downregulation of RAD51, a key
mediator of HRR, was observed in multiple cancer cell types
FIGURE 1 | DNA damage response. DNA damage is caused by endogenous agent oxygen species (ROS) or exogenous agents such as UV light, ionizing radiation
(IR) and chemotherapy agents. DNA damage response (DDR) is induced to deal with the lesions, including signal transduction, transcriptional regulation, cell-cycle
checkpoints, induction of apoptosis, multiple DNA repair pathways as well as damage tolerance processes. DNA repair pathways include nuclear and mitochondrial
DNA repair pathways. Direct repair, BER, MMR and recombinational repair (HR andNHEJ) are existence in both nuclear andmitochondrial repair systems. NER has
been reported only appearance in nucleus, and the existence of TLS pathway in mitochondria is unknown. NDNA, nuclear DNA; MtDNA, mitochondrial DNA; BER, base
excision repair; HR, homologous recombination repair; NHEJ, non-homologous end joining; MMR, mismatch repair; TLS, translesion synthesis; NER, nucleotide
excision repair.
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induced by hypoxia, suggesting that the hypoxic tumor
microenvironment can suppress the HRR pathway to cause
genetic instability (Bindra et al., 2004; Lu et al., 2011). Tumor
hypoxia also regulated the DDR by driving alternative splicing
(Memon et al., 2016). Study in human pulmonary epithelial cells
has found that the acidic conditions delayed DNA damaging
compounds benzo[a]pyrene (B[a]P) metabolism and inhibited
NER capacity, ultimately enhanced B[a]P-induced DNA damage
(Shi et al., 2017). Recent studies have shown that extracellular
nutrients have significant effects on genome integrity. Glutamine
is the main source of carbon and nitrogen for tumor cells. Lack of
glutamine led to DNA alkylation damage by inhibiting ALKBH
activity and increased the sensitivity of cancer cells to alkylating
agents (Tran et al., 2017). Glucose starvation also enhanced
radiosensitivity of tumor cells by reducing DNA double-strand
break (DSB) repair (Ampferl et al., 2018). Thus, the dysregulation
of DNA repair pathways can contribute to the development of
cancer by promoting genomic instability and mutation in
mammal cells.
TARGETING DNA REPAIR PATHWAYS IN
CANCER THERAPY
The most common cancer treatments, including chemo- or
radiotherapy, are designed to induce cell death by direct or
indirect DNA damage. However, tumor cells can initiate DNA
repair pathways to resist these anticancer agents during chemo-
or radiotherapy. Therefore, combination of the nuclear or
mitochondrial DNA repair pathway inhibitors with anticancer
agents may increase the tumor cell sensitivity to these agents.
O-6-Methylguanine-DNAMethyltransferase
(MGMT)
The role of MGMT is to remove alkyl adducts from the O6
position of guanine. Thus, the protective effect of MGMT could
diminish the cytotoxic effects of alkylating agents (Middleton and
Margison, 2003), suggesting that MGMT activity is likely to be a
useful marker of the sensitivity of cancer cells to alkylating agents.
It has been reported that high MGMT expression in tumor cell is
associated with the resistance to 1,3- bis- (2-chloroethyl) -1-
nitrosourea (BCNU) and temozolomide (TMZ) (Happold et al.,
2018; Hsu et al., 2018), which target the O6-position of guanine,
resulting in cytotoxic and mutagenic DNA adducts (Rabik et al.,
2006). Recently, researchers found that MGMT-mediated the
resistance to DNA alkylating agents in cancer cell is profoundly
dependent on the DNA repair enzyme PARP. Combination of
temozolomide with PARP inhibitors (PARPi) in MGMT-positive
cancer cells enhanced the anticancer effects (Erice et al., 2015; Jue
et al., 2017).
The inactivation of MGMT in tumor cells has been
appreciated as a therapeutic target for sensitizing cells to
O6-alkylating agents (Maki et al., 2005). In vitro and in vivo
studies demonstrated that O6-Benzylguanine (O6-BG), a
typical pseudo-substrate that was developed to inactivate
MGMT, in combination with O6-alkylating agents increased
the therapeutic efficacy of chemotherapeutic alkylating agents
(Maki, Murakami, 2005). Lomeguatrib (called O6-(4-
bromothenyl) guanine, as well as PaTrin-2), another
pseudo-substrate tested in clinical trials, has been shown to
increase the therapeutic index of methylating agent
temozolomide in nude mice bearing A375M human
melanoma xenografts and patients with advanced solid
tumors (Middleton et al., 2002; Ranson et al., 2006).
Bobustuc GC et al. demonstrated that inhibition of MGMT
suppressed the expression of survivin and enhanced the
cytotoxicity of gemcitabine in pancreatic cancer (Bobustuc
et al., 2015). Another approach to MGMT inactivation is to
silence the MGMT gene expression through its promoter
methylation. Several studies in animal models have
suggested that the therapy of MGMT gene silence was able
to overcome TMZ resistance and increase tumor cell death
(Viel et al., 2013). Clinical study indicated that patients with
glioblastoma containing a methylated MGMT promoter
obtained more benefits from TMZ than those who did not
have a methylated MGMT promoter (Hegi et al., 2005). Lately,
it has been confirmed that MGMT gene methylation can be a
biomarker for temozolomide (TMZ) treatment and a potent
prognostic factor in patients with GBM (Kim et al., 2012;
Iaccarino et al., 2015; Zhao et al., 2016; Binabaj et al., 2018).
However, according to the data from National Cancer database
(NCDB) indicated that only 4.9% of GBM patients have
MGMT promoter methylation. Even though MGMT
promoter methylation status has prognostic value, it is
ignored in the United States (Lee et al., 2018). More
researches need to conduct to identify the prognostic value
of MGMT promoter methylation in tumor patients responding
to alkylating agents.
Base Excision Repair
A number of investigations have shown that inhibition of BER
pathway can enhance the sensitivity of cancer cells to alkylating
agents and radiotherapy (Neijenhuis et al., 2005; Gao et al., 2019).
The primary methods to prevent the activity of BER pathway
focus on the development of AP endonuclease 1 (APE1) or Poly
(ADP-ribose) polymerase (PARP) inhibitors.
Several studies indicated that methoxyamine (MX), a small
alkoxyamine that can bind with the free aldehyde of AP site to
prevent APE1 cleavage at AP sites, thereby inhibiting APE-1
endonuclease activity. Combined treatment with
chemotherapeutic alkylating agent such as TMZ and BCNU
could reinforce the cytotoxicity of alkylating agent by targeting
BER pathway (Liu et al., 2003; Montaldi and Sakamoto-Hojo,
2013). Recently, based on preclinical studies, several clinical trials
were conducted, for example combination therapy with MX and
TMZ in patients with advanced solid tumors has completed
(NCT00892385). Currently, phase Ⅰ clinical trials of MX in
combination of TMZ is undergoing in patients with relapsed
solid tumors and lymphomas (NCT01851369). MX combination
with pemetrexed disodium, cisplatin, is now investigating in
phase Ⅰ/II stage in patients with advanced malignant solid
neoplasm (NCT02535312). Lucanthone, a topoisomerase II
inhibitor as well as an APE1 endonuclease inhibitor, has been
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shown to reinforce the cell killing effect of alkylating agents in
human breast cancer cell line MDA-MB-231 (Luo and Kelley,
2004). Lucanthone combination with radiation and TMZ in GBM
patients was tested in phase Ⅱ clinical trial (NCT01587144).
However, it was terminated in 2016. Another phase II clinical
trial investigating lucanthone combination with radiation in
patients with brain metastases from non-small cell lung cancer
was withdrawn due to drug issues (NCT02014545).
PARP family is composed of 17 members, of which PARP1 and
PARP2 are well-recognized DNA damage sensors, especially PARP1.
PARP1 detect the region of damaged DNA and play a key role in
several DNA repair pathway including BER, HHR and MMEJ
(Konecny and Kristeleit, 2016). While PARP1 is best studied in
BER and the mechanism of PARP inhibitor (PARPi) is based on
trapping PARP1 on SSBs DNA site to inhibit BER repair. Finally, it
converted SSBs into DSBs and impelled cell death in HR-deficiency
tumor, for example BRCA1/2 mutations, RAD51 deficiency
(Figure 2) (Konecny and Kristeleit, 2016; Brown et al., 2017; Lord
and Ashworth, 2017; Oplustil O’Connor et al., 2016). In 2005, two
pre-clinical researches published in nature indicated that BRCA1 or
BRCA2 deficient cells highly sensitized to PARP inhibition (Farmer
et al., 2005; Bryant et al., 2005). Based on the concept of “synthetic
lethality”-targeting either gene alone in a synthetic lethal pair is
tolerated, but simultaneous targeting both genes is lethal, researchers
applied PARPi to BRCA mutation tumors (Dhillon et al., 2016).
Several clinical trials using PARPi including Olaparib, Veliparib,
Rucaparib (Table 1) as monotherapy for the treatment of patients
with germline BRCA1/2 mutation tumors including advanced breast
cancer, ovarian cancer, pancreatic cancer and prostate cancer
presented significantly antitumor effect (Kaufman et al., 2015;
Robson et al., 2017; Moore et al., 2018; Golan et al., 2019).
Olaparib as maintenance therapy also significantly prolonged
progression-free survival in advanced ovarian cancer patients with
HRD-positive tumors who have achieved first-line standard therapy
including bevacizumab. It has been approved by FDA for
utilization of Olaparib in patients with advanced germline
FIGURE 2 | Mechanism and function of PARP and PARP inhibitors. The catalytic function of PARP1 is activated through binding to the SSBs site cuased by
alkylating agents. Activated PARP1 undergo PARylation and recruitment of a serials of key DNA repair effectors involved in BER to repair DNA lesion. Finally, PARP1
release from DNA and regain inactive state. PARP inhibitors binds the catalytic site of PARP and impaired of the enzymatic activity of PARP which “trap” PARP1 on DNA,
results in suppression of the catalytic cycle of PARP1 and BER. Trapping PARP1 on DNA lesion also collapses DNA replication fork, therefore transforming SSBs
into genotoxic DSBs. This type of DNA lesion would normally induce HR for repairing damaged DNA. However, if HR-defective exist in tumor cells, including BRCA1/2
deficiency or mutation, another less effective and error-prone DSBs repair pathway NHEJ or alt-NHEJ could be utilized, which causing genomic instability, chromosomal
fusions/translocations and subsequently inducing cell death. SSBs, single-strand breaks; DSB, double-strand break; BER, base excision repair; alt-NHEJ, alternative
nonhomologous end joining; NHEJ, non-homologous end joining; HR, homologous recombination repair.
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Disease state Intervention/treatment NCT number Status
PARP1/
PARP2
BER Olaparib (AZD-2281) Phase II Metastatic renal cell carcinoma with DNA
repair gene mutations
Olaparib NCT03786796 Recruiting
Phase II Mesothelioma with homologous
recombination deficiency
Olaparib NCT04515836 Not yet
recruiting
Phase II Non-BRCA metastatic breast cancer (MBC) Olaparib NCT03367689 Recruiting
Phase II Metastatic urothelial cancer with somatic DNA
damage response (DDR) alterations
Olaparib NCT03448718 Recruiting
Phase II Metastatic breast cancer with BRCA1 and/or 2
promoter methylation
Olaparib NCT03205761 Recruiting
Phase II Cisplatin-resistant germ cell tumor Olaparib NCT02533765 Active, not
recruiting
Phase I Advanced cancer Olaparib, AZD5363 NCT02338622 Completed
Phase I Triple negative breast cancer (TNBC) Olaparib, radiation therapy NCT03109080 Active, not
recruiting
Phase Ⅲ HER2-ve metastatic breast cancer patient Olaparib NCT03286842 Active, not
recruiting
Phase Ⅳ BRCA or HRR + mutated ovarian cancer Olaparib NCT02476968 Active, not
recruiting
Niraparib Phase I Advanced solid tumors Niraparib NCT03497429 Completed
Phase II Uterine serous carcinoma Niraparib NCT04080284 Recruiting
Phase I EGFR-mutated advanced lung cancer Niraparib, osimertinib NCT03891615 Recruiting
Phase II Pancreatic cancer Niraparib NCT03601923 Recruiting
Phase I Solid tumors SYD985, niraparib NCT04235101 Recruiting
Phase Ⅲ Ovarian cancer Nirapairb NCT03709316 Recruiting
Talazoparib Phase I BRCA mutation-associated breast and ovarian
cancers, pancreatic and small cell lung cancer
Talazoparib NCT01286987 Completed
Phase I Leukemia with cohesin complex mutation Talazoparib NCT03974217 Recruiting
Phase II Advanced cancer with DNA repair variations Talazoparib NCT04550494 Not yet
recruiting
Phase II Triple negative breast cancer Talazoparib, ZEN003694 NCT03901469 Recruiting
Veliparib (ABT-888) Phase I Pancreatic cancer Veliparib, gemcitabine,
radiation
NCT01908478 Completed
Phase I Refractory Solid Tumors Veliparib, VX-970, cisplatin NCT02723864 Active, not
recruiting





Phase II Metastatic breast cancer with BRCA1/2 gene
mutation
ABT-888, temozolomide NCT01009788 Active, not
recruiting




Phase I Advanced malignant solid neoplasm Dinaciclib, veliparib NCT01434316 Recruiting
Rucaparib Phase I Advanced solid tumor Rucaparib, camsylate NCT03521037 Active, not
recruiting
Phase II Nonmetastatic, hormone-sensitive prostate
cancer
Rucaparib NCT03533946 Recruiting
Phase I Metastatic castration resistant prostate cancer Rucaparib, enzalutamide,
abiraterone
NCT04179396 Recruiting
Phase II High-grade serous or endometroid ovarian
cancer
Rucaparib, nivolumab NCT03824704 Active, not
recruiting
Phase II Solid tumors and with deleterious mutations in
HRR genes
Rucaparib NCT04171700 Recruiting




Phase I/II Relapsed solid tumors and lymphomas TRC102 NCT01851369 Recruiting
Phase I/II Solid tumors or mesothelioma Cisplatin, methoxyamine,
pemetrexed disodium
NCT02535312
Phase I Stage IIIA-IV non-small cell lung cancer Radiation, cisplatin NCT02535325 Active, not
recruiting
APE1/Ref-1 BER APX3330 (E3330) Phase I Advanced solid tumors APX3330 NCT03375086 Completed
DNA-PK NHEJ MSC2490484A
(M3814)
Phase I Locally advanced rectal cancer M3814, avelumab,
radiation
NCT03724890 Recruiting
Phase I Advanced solid tumor Radiation, cisplatin,
MSC2490484A
NCT02516813 Recruiting
Phase I/II Locally advanced rectal cancer M3814, capecitabine,
radiation
NCT03770689 Recruiting





NHEJ CC-115 Phase I Advanced solid tumors, hematologic
malignancies
CC-115 NCT01353625 Active, not
recruiting
(Continued on following page)
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BRCA-mutated ovarian cancer following three or more prior
lines of chemotherapy (Kim et al., 2015). On May 19, 2020, the
FDA also approved Olaparib for patients with metastatic
castration-resistant prostate cancer (mCRPC) carrying HRR
gene-mutated based on NCT02987543. PAPR1 inhibitors in
combination with IR or with other different anticancer agents
are currently undergoing clinical trials for treatment of
patients with BRCA1/2 mutation or HRR-deficiency
advanced solid tumors, which shown promising clinical
activity (Bang et al., 2017; Wilson et al., 2017; Loibl et al.,
2018; Coleman et al., 2019; Farago et al., 2019;
Konstantinopoulos et al., 2019; Liu et al., 2019).
Double Strand Breaks Repair
Among various DNA lesions, DSBs is the leading lethal
damage that leads to cell death and genetic mutations.
DNA-dependent protein kinase (DNA-PK), a member of
the PI3K-related protein kinase (PIKK) family, is involved
in DSBs repair pathway via non-homologous end joining
(NHEJ) (Jette and Lees-Miller, 2015). It has been reported
that DNA-PK activity plays a role in chemo-radiotherapy
resistance (Wang Y. et al., 2018; Stefanski et al., 2019;
Alikarami et al., 2017; Liu et al., 2015). Selective DNA-PK
inhibitor have been developed, including NU7026 (Dolman
et al., 2015), NU7441 (Yang et al., 2016), IC87361 and
SU11752 (Shinohara et al., 2005). They could inhibit DSBs
repair pathway and enhance the sensitivity of cancer cells to
ionizing radiation or/and chemo-potentiation such as
doxorubicin (Ciszewski et al., 2014). The combination of
DNA-PK inhibitor M3814 with type II topoisomerase
inhibitors, including doxorubicin, etoposide and pegylated
liposomal doxorubicin, enhanced the efficacy of type II







Disease state Intervention/treatment NCT number Status





AZD1390 Phase I Brain cancer Radiation, AZD1390 NCT03423628 Recruiting






Phase II Biliary tract cancer AZD6738, durvalumab NCT04298008 Recruiting
Phase I Leukemia, myelodysplastic syndrome AZD6738 NCT03770429 Recruiting
Phase II Relapsed small cell lung cancer subjects Durvalumab, AZD6738 NCT04361825 Enrolling by
invitation
Phase II Clear cell renal cell carcinoma, locally
advanced pancreatic cancer, locally advanced
malignant solid neoplasm
AZD6738, olaparib NCT03682289 Recruiting
Phase I Refractory cancer AZD6738, paclitaxel NCT02630199 Recruiting
Phase II Recurrent ovarian cancer Olaparib pill, AZD6738 NCT03462342 Recruiting
Phase II IDH1 and IDH2 mutant tumors Ceralasertib, olaparib NCT03878095 Recruiting
VE-822 (VX-970,
M6620, berzosertib)
Phase II Solid tumor, leiomyosarcoma, osteosarcoma M6620 NCT03718091 Recruiting
Phase1/II Small cell cancers and extrapulmonary small
cell cancers
Topotecan, VX-970 NCT02487095 Recruiting
Phase I Refractory solid tumors Veliparib, VX-970, cisplatin NCT02723864 Active, not
recruiting
Phase II Small cell lung cancers and small cell cancers








CHK1 HR Prexasertib Phase II Triple negative breast cancer LY3023414, prexasertib NCT04032080 Recruiting
Phase II Recurrent or refractory solid tumors Prexasertib NCT02808650 Active, not
recruiting
Phase I/II Desmoplastic small round cell tumor,
rhabdomyosarcoma
Prexasertib, irinotecan NCT04095221 Recruiting
Phase II Platinum-resistant or refractory recurrent
ovarian cancer
Prexasertib NCT03414047 Active, not
recruiting
Phase I Advanced solid tumors Prexasertib, olaparib NCT03057145 Active, not
recruiting
MK-8776 Phase I Acute leukemias MK-8776, cytarabine NCT00907517 Terminated





Phase II Uterine serous carcinoma Adavosertib NCT04590248 Not yet
recruiting
Phase I Advanced solid tumors Adavosertib NCT04462952 Recruiting








Abbreviations: PARP, Poly (ADP-ribose) polymerase; APE1, AP endonuclease 1; Ref-1, redox factor-1; DNA-PK, DNA-dependent protein kinase; mTOR, mammalian target of rapamycin;
ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; CHK1, checkpoint kinase 1; WEE1, Wee1-like protein kinase.
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topoisomerase inhibitors in ovarian cancer xenografts (Wise
et al., 2019). Several novel DNA-PK inhibitors including
MSC2490484A, VX-984 (M9831), M3814 are under clinical
trial as single-agent or combination with Chemo-radiotherapy
(Table 2). Alexander K. Tsai et al. recently found that NU7441
combination with a multikinase inhibitor regorafenib altered
immune microenvironment of melanomas and enhanced the
efficacy of various immunotherapies (Tsai et al., 2017).
Ataxia-teleangectasia mutated (ATM) and ATM-RAD3-
related (ATR) protein, like DNA-PK protein, are the members
of PIKK family. They work as a transducer of the DSB signal, and
are involved in the repair of DNA DSBs (Weber and Ryan, 2015).
A large of ATM inhibitors, including KU-55933, KU-60019, KU-
59403, CP-466722, AZ31, AZ32, AZD0156, and AZD1390, have
been developed and their antitumor effects have been investigated
(Jin and Oh, 2019). It has been reported that human tumor cells
treated with KU-55933, a specific inhibitor of the ATM kinase,
could sensitize tumor cells to the cytotoxic effects of IR and DNA
DSBs-inducing chemotherapeutic agents such as etoposide,
doxorubicin, and camptothecin (Hickson et al., 2004; Hoey
et al., 2018). KU-60019, an improved ATM kinase inhibitor,
acts as a highly effective radio-sensitizer in human glioma cells
(Biddlestone-Thorpe et al., 2013). AZD0156, a newly discovered
ATM inhibitor, has the potential to promote the survival of
leukemia-bearing mice and now is under clinical trial
(Morgado-Palacin et al., 2016). Preclinical study demonstrated
that ATM inhibitor AZD1390 enhanced the radiosensitivity of
tumor cells and extended animal survival in preclinical brain
tumor models (Durant et al., 2018). AZD1390, as a
radiosensitizer, is now undergoing two clinical trials in
patients with brain cancer (NCT03423628) or non small cell
lung cancer (NCT04550104). Many inhibitors aiming at both
ATM and DNA-PK have been reported to have great potential as
a chemo- and radiotherapy sensitizing agents in cancer therapy
(Powell and Bindra, 2009).
The cell cycle checkpoint kinases CHK1 and CHK2 are
downstream substrates of ATM /ATR, which act as the
“central transducers” of the DDR (Pilie et al., 2019).
Activation of these pathways is essential for the proper
regulation of checkpoint and DNA repair (Smith et al., 2010).
The ATM–Chk2 and ATR–Chk1 pathways respond to different
DNA damages, ATM is activated at DSBs, whereas ATR is
recruited to tracts of ssDNA (Di Benedetto et al., 2017).
Subsequently, CHK1 and CHK2 activated by ATR and ATM
respectively upon their recruitment to DNA damage sites. Protein
kinase WEE1 functioned as furthest downstream in ATR/CHK1
pathway, which is indirectly regulated by DNA damage (Cleary
et al., 2020). WEE1 actives the G2/M cell cycle checkpoint by
impeding cyclin-dependent kinase 1 and 2 (CDK1/2) activity,
thereby inducing cell cycle arrest and promoting DNA damage
repair. Inhibition of WEE1 causes aberrant DNA replication and
replication-dependent DNA damage in cells by suppressing
CDK2 (Guertin et al., 2013). Recently, compounds targeting
CHK1 are currently in clinical trials (Table 1). The first-in-
class WEE1 kinase inhibitor AZD1775 is also undergoing a
series of clinical trials as monotherapy or in combination with
other therapies (Table 1).
mtDNA Repair Pathway
Recently, the exploration of novel anticancer strategies aiming at
the differences in mitochondrial function and structure between
normal cells and cancer cells has received intensive attention
(Porporato et al., 2018). However, there are few studies that have
discovered new anticancer approaches via targeting mtDNA
repair pathway.
Like nDNA, efficient mtDNA repair pathway, especially BER
pathway that mainly repairs ROS-induced lesion, may play an
important role in cellular resistance to cancer therapeutic agents.
MtDNA D-loop mutations were common in gastrointestinal cancer
and correlated with carcinoma progression (Wang B. et al., 2018). It
has been found that human breast cancer cells defective of mtDNA
repair are more sensitive to oxidative damage than the control cells
(Shokolenko et al., 2003). Grishko V I et al indicated that mtDNA
repair pathways played an important role in protecting cells against
ROS in normal HA1 Chinese hamster fibroblasts (Grishko et al.,
2005). Another study clarified that mtDNA repair capacity was
important for cellular resistance to oxidative damage by increasing
their viability following exposure to oxidative stress (Shokolenko
et al., 2003). Ueta E et al demonstrated that downregulation of the
mtDNA repair-associated molecules, mitochondrial transcription
factor A (mtTFA) and Polγ by using inhibitors of PI3K/Akt
signaling in oral squamous cell carcinoma cells (OSC) increased
the susceptibility of radio-sensitive OSC cells and radio-resistant
OSC cells to gamma-rays (Ueta et al., 2008). This observation
implied that PI3K/Akt signal inhibitors can suppress mtDNA
repair capacity. Thus, these inhibitors combined with ionizing
irradiation or chemotherapeutic drugs may be utilized as an
effective strategy in cancer therapy.
DNA glycosylases are involved in the initiation step of BER that
recognizes and removes the abnormal base (Anderson and
Friedberg, 1980). 8-OxoG-recognizing DNA glycosylase 1
(OGG1) is an important DNA glycosylase for repair of 8-
oxoguanine (8-oxoG), which is one of the major DNA lesions
both of the nDNA and mtDNA, especially in mtDNA (Rachek
et al., 2002). It has been found that tumor cells harboring
overexpressed recombinant OGG1 were more proficient at
repairing of oxidative damage to mtDNA, and had increased
cellular survival under oxidative stress (Rachek et al., 2002;
Yuzefovych et al., 2016). We previously found that Sirt3, a major
mitochondrial NAD+-dependent deacetylase, physically associated
with OGG1 and deacetylated this DNA glycosylase, and that
deacetylation by Sirt3 prevented the degradation of the OGG1
protein and controlled its incision activity (Cheng et al., 2013).
We further showed that regulation of the acetylation and turnover of
OGG1 by Sirt3 played a critical role in repairingmitochondrial DNA
(mtDNA) damage, protecting mitochondrial integrity, and
preventing apoptotic cell death under oxidative stress. We
observed that following ionizing radiation, human tumor cells
with silencing of Sirt3 expression exhibited oxidative damage of
mtDNA, as measured by the accumulation of 8-oxoG and 4,977
common deletion, showed more severe mitochondrial dysfunction,
and underwent greater apoptosis, in comparison to the cells without
silencing of Sirt3 expression. Our results not only reveal a new
function and mechanism for Sirt3 in defending the mitochondrial
genome against oxidative damage and in protecting from the
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genotoxic stress-induced apoptotic cell death, but also provide
evidence supporting a new mtDNA repair pathway. Recently,
researchers also proved that overexpression of mitochondrial
OGG1 decreased breast cancer progression and metastasis
(Yuzefovych et al., 2016).
In conclusion, combination of DNA repair pathway inhibitors
with anticancer agents may enhance the tumor sensitivity to
certain chemotherapeutic drugs and radiation. More effective and
less toxic DNA-damaging agents have been developed and
carried out in preclinical studies (Table 2). Based on the
preclinical data, a number of clinical trials have been launched
to test whether targeting DNA repair pathways can reinforce the
efficacy of some anticancer drugs and benefit cancer patients
(Table 1).
THE RELATIONSHIP BETWEEN DNA
REPAIR PATHWAYS AND CANCER
THERAPEUTIC RESISTANCE
Resistance to cancer therapy remains the leading cause of treatment
failure in cancer patients. DNA repair capacity (DRC) of tumor cells
has been known to involve in drug resistance, including
chemoradiotherapy, targeted therapy and immunotherapy. DNA
damage inducing drug cisplatin is one of the most widely employed
chemotherapeutic drugs. In a murine model of human lung cancer,
tumor cells were initially effective with cisplatin treatment, but
resistant emerged after prolonged treatment (Oliver et al., 2010).
Cisplatin-resistant tumor cells exhibited higher level of DNA
damage repair related genes and DRC, inhibition of NER
pathway significantly enhanced the sensitivity of tumor cells to
cisplatin (Oliver,Mercer, 2010;Wang et al., 2011). Low expression of
53BP1, a DDR protein involved in NHEJ, was associated with higher
local recurrence in triple negative breast cancers (TNBC) patients
treated with breast-conserving surgery and radiotherapy, indicating
that 53BP1 may be a predictor of radio-resistance (Neboori et al.,
2012). PTEN Y240 phosphorylation induced by ionizing radiation
(IR), a standard treatment for glioblastoma (GBM) patients,
promoted therapeutic resistance by enhancing DNA repair (Ma
et al., 2019). Inhibiting DNA repair kinases could also prevent
doxorubicin (DOX) resistance in breast cancer cells (Stefanski
et al., 2019). Abnormal DNA repair activity was found in CDK4/
6 inhibitors palbociclib-resistant breast cancer cells, whereas PARP
inhibitors, olaparib and niraparib treatment could significantly
inhibit palbociclib-resistant cancer cell viability (Kettner et al.,
2019). In the recent years, immunotherapy is a major
breakthrough in the field of cancer treatment. Therefore, the role
of DDR in tumor immunotherapy has attracted much attention.
Studies have shown deficiency of a specific DNA repair pathway was
associated with immune checkpoint blockade (ICB) response. For
example,MMRhas been reported as a critical biomarker of response
to immune checkpoint inhibitors in cancer (Le et al., 2017).
Alterations in genes encoding MMR proteins often contribute to
frameshift mutations, resulting in neoantigen generation (Germano
et al., 2017). Phase II clinical trials proved that mismatch
repair–deficient tumors exhibited higher responsive to PD-1
blockade compared with mismatch repair–proficient
tumors(Asaoka et al., 2015). Based on lines of pre-clinical






Direct repair MGMT Pancreatic cancer cells; combination with HDACis in ovarian
cancer
Wu et al. (2019), Shi et al.
(2020)
Lucanthone BER APE1 Glioblastoma multiforme (GBM) cell Chowdhury et al. (2015)
CRT0044876 BER APE1 Colon cancer cell lines Seo and Kinsella (2009)
Methoxyamine BER APE1 Combination with pemetrexed in non-small-cell lung cancer cells
and xenografts
Oleinick et al. (2016)
APX3330 (E3330) BER APE1/Ref-1 Bladder cancer (Fishel et al., 2019)
RI-1 HR RAD51 Combination with olaparib in breast cancer cells with wild-type
PTEN; combination with radiation in glioma stem cells
King et al. (2017), Zhao et al.
(2017)
B02 HR RAD51 Combination with radiation in glioma stem cells; combination with
clinically approved anticancer agents in breast cancer cell
Huang and Mazin (2014), King
et al. (2017)
AG-14361 BER PARP1 Combination with lestaurtinib in breast cancer cells Vazquez-Ortiz et al. (2014)
A-966492 BER PARP1/2 Combination with topotecan and radiotherapy on glioblastoma
spheroids
Koosha et al. (2017)
KU-55933 HR ATM Combination with radiotherapy on glioblastoma spheroids Carruthers et al. (2015)
ETP-46464 HR ATM/ATR,
mTOR
Single or combination with cisplatin in platinum-sensitive and
-resistant ovarian, endometrial and cervical cancer cell lines
Teng et al. (2015)
VE-821 HR ATR Combination with BETi in myc-induced lymphoma cells Muralidharan et al. (2016)
AZ20 HR ATR Colorectal adenocarcinoma tumor cells Foote et al. (2013)
CGK733 HR ATM/ATR Human breast cancer cells Alao and Sunnerhagen (2009)
NU7026 NHEJ DNA-PK Combination with carbon ion irradiation in non-small cell lung
cancer cell
Ma et al. (2015)
NU7441 NHEJ DNA-PK Combination with radiotherapy in non-small cell lung cancer cell Sunada et al. (2016)
Abbreviations: MGMT, O-6-methylguanine-DNA methyltransferase; APE1, AP endonuclease 1; Ref-1, redox factor-1; RAD51, DNA repair protein RAD51 homolog 1; PARP, Poly (ADP-
ribose) polymerase; ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; mTOR, mammalian target of rapamycin; DNA-PK, DNAdependent protein kinase;
BETi, BET inhibitors.
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and clinical evidence, the US Food and drug Administration
(FDA) has approved anti-PD-1 antibodies for the treatment of
patients with MMR-deficient (Ruiz-Bañobre and Goel, 2019).
On the contrary, researchers also found that colorectal cancer
(CRC) patient with DNA mismatch repair deficiency
(dMMR)/a high-level of microsatellite instability (MSI-H)
exhibited intrinsic resistance to immune checkpoint immune
checkpoint inhibitor (Gurjao et al., 2019). Metastatic urothelial
carcinoma (mUC) shown relatively low response rates to PD-1/
PD-L1 blockade (15–24%), whereas the presence of DDR gene
mutations is a potential marker of clinical benefit from anti-PD-
1/PD-L1 immune checkpoint inhibitors in mUC (Teo et al., 2018).
Preclinical studies have also revealed that suppression of PARP
induced PD-L1 expression and consequently caused
immunosuppression (Jiao et al., 2017). Researches also elucidated
that PARP inhibitor olaparib enhanced CD8+ T-cell
recruitment and activation by activating the cGAS/STING
pathway in BRCA1-deficient triple-negative breast cancer
(Pantelidou et al., 2019). Therefore, multiple combination
studies involving immune checkpoint inhibitors with DDR
inhibitors are undergoing clinical trials, such as combination
PARP inhibitor Niraparib and anti-PD-1 antibody
pembrolizumab in patients with triple-negative breast
cancer or ovarian cancer (NCT02657889). In the phase I,
multi-center, dose-escalation study, patients with advanced
solid tumors will receive WEE1 inhibitor AZD1775
(Adavosertib) in combination with MEDI4736
(durvalumab) (NCT02546661). These studies suggest that
DRC plays a key role in cancer therapy resistance,
therefore, evaluation of DNA repair phenotype before
treatment could be of great value in clinical management of
clinical therapeutic drugs or modalities.
A number of DDR inhibitors have currently come to market
or under clinical development. PARP inhibitors are the first
clinically approved DDR drugs based on the concept of
“synthetic lethal” (Lord and Ashworth, 2017). PARP
inhibitors have been widely used for cancer patients with
BRCA1/2 mutation or HRR deficiency and showed promising
clinical activity. However, resistance inevitably developed in the
majority of patients and led to treatment failure. The
mechanism of resistance to PARP inhibitors can be innate or
acquired though clinical and preclinical studies. Preclinical
studies demonstrated that overexpression of P-glycoprotein
drug efflux transporter implicated in intrinsic resistance to
Olaparib (Henneman et al., 2015). Resumption of
PARformation due to poly (ADP-ribose) glycohydrolase
(PARG) depletion conferred acquired resistance to PARP
inhibition in BRCA2-deficient tumor cells (Gogola et al.,
2018). PARP1 p. T910A mutation could override PARP1
inhibition promoted the secondary failure of Olaparib
treatment (Gröschel et al., 2019). Another mechanism
leading to resistance may restoration of HRR function or re-
construction of replication fork stability by increasing RAD51
expression or re-expressing BRCA1/2 (Ter Brugge et al., 2016;
Quigley et al., 2017; Clements et al., 2018; Lim et al., 2018;
Marzio et al., 2019). Upregulation of certain oncogenic
pathways such as Wnt/β-catenin signaling pathway or DDR
related protein may also confer cancer cells insensitive to PARP
inhibitors and providing some rationale for combination
strategies with PARP inhibitors (Fukumoto et al., 2019;
Watson et al., 2019; Liu et al., 2020).
CONCLUSION AND PERSPECTIVES
Based on the relationship between DNA repair pathways and
cancer development and progression, a new therapeutic
strategy has emerged to increase the efficacy of DNA
damaging agents through combination with inhibitors of
DNA repair pathways. The inhibitors of several DNA repair
pathways have been developed, and some of them are currently
undergoing clinical trials. The therapeutic benefits of these
agents should be further evaluated in cancer treatment, and the
more specific inhibitors should be developed to reduce the
adverse effect on normal tissues and cells. Many studies have
demonstrated that the inhibition of DNA repair pathways may
be an important way in anticancer therapies. However, we
should realize that use of certain inhibitors of DNA repair
pathways may have potential drawbacks. The combination of
IR or chemotherapeutic agents with inhibitors of DNA repair
pathway may increase the mutagenic lesions in surviving cells
and lead to the development of secondary tumors. More
attentions have been paid to the relationship between
defective nuclear DNA repair pathway and therapeutic
resistance but less about the association between the
mitochondrial repair pathway and cancer cells. Due to the
difference in mtDNA between cancer cells and normal cells,
the development of mtDNA repair pathway inhibitors that can
reduce the adverse effects to normal cells may be a more
effective strategy to enhance the anticancer therapy than
targeting nDNA. A better understanding on the
mechanisms of mtDNA repair pathways shall facilitate the
development of new effective chemo- and radiosensitizers by
targeting mtDNA repair pathway in cancer therapy.
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